{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:53:56Z","timestamp":1787961236029,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Servier France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00787-024-02587-4","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T18:02:00Z","timestamp":1728583320000},"page":"1603-1614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-4754","authenticated-orcid":false,"given":"Celso","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6070-4323","authenticated-orcid":false,"given":"Joerg M.","family":"Fegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-0793","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Picarel-Blanchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Truffaut-Chalet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"P\u00e9n\u00e9laud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-7757","authenticated-orcid":false,"given":"Jan","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"2587_CR1","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(16)00648-6","volume":"387","author":"AH Mokdad","year":"2016","unstructured":"Mokdad AH, Forouzanfar MH, Daoud F, Mokdad AA, El Bcheraoui C, Moradi-Lakeh M et al (2016) Global burden of diseases, injuries, and risk factors for young people\u2019s health during 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 387:2383\u20132401. https:\/\/doi.org\/10.1016\/S0140-6736(16)00648-6","journal-title":"Lancet"},{"issue":"7","key":"2587_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamapsychiatry.2020.0279","volume":"77","author":"R Mojtabai","year":"2020","unstructured":"Mojtabai R, Olfson M (2020) National trends in mental health care for US adolescents. JAMA Psychiat 77(7):703\u2013714. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0279","journal-title":"JAMA Psychiat"},{"issue":"Suppl 2","key":"2587_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su7102a1","volume":"71","author":"RH Bitsko","year":"2022","unstructured":"Bitsko RH, Claussen AH, Lichstein J, Black LI, Jones SE, Danielson ML et al (2022) Mental health surveillance among children\u2014United States, 2013\u20132019. MMWR Suppl 71(Suppl 2):1\u201342. https:\/\/doi.org\/10.15585\/mmwr.su7102a1","journal-title":"MMWR Suppl"},{"key":"2587_CR4","unstructured":"Sadler K, Vizard T, Ford T (2018) NHS Digital; Mental health of children and young people in England, 2017: summary of key findings.https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/mental-health-of-children-and-young-people-in-england\/2017\/2017"},{"key":"2587_CR5","unstructured":"World Health Organization Regional Office for Europe (2018) Adolescent mental health in the European Region, 2018. https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0005\/383891\/adolescent-mh-fs-eng.pdf. Accessed 24 May 2022"},{"key":"2587_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators (2021) Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398:1700\u20131712. https:\/\/doi.org\/10.1016\/S0140-6736(21)02143-7","journal-title":"Lancet"},{"issue":"11","key":"2587_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamapediatrics.2021.2482","volume":"175","author":"N Racine","year":"2021","unstructured":"Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S (2021) Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis. JAMA Pediatr 175(11):1142\u20131150. https:\/\/doi.org\/10.1001\/jamapediatrics.2021.2482","journal-title":"JAMA Pediatr"},{"key":"2587_CR8","first-page":"1","volume":"18","author":"U Panchal","year":"2021","unstructured":"Panchal U, Salazar de Pablo G, Franco M, Moreno C, Parellada M, Arango C, Fusar-Poli P (2021) The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. Eur Child Adolesc Psychiatry 18:1\u201327","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"2587_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/2167702612457599","volume":"1","author":"P Rohde","year":"2013","unstructured":"Rohde P, Lewinsohn PM, Klein DN, Seeley JR, Gau JM (2013) Key characteristics of major depressive disorder occurring in childhood, adolescence, emerging adulthood, adulthood. Clin Psychol Sci 1(1):41\u201353. https:\/\/doi.org\/10.1177\/2167702612457599","journal-title":"Clin Psychol Sci"},{"key":"2587_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tins.2008.01.004","volume":"31","author":"SL Andersen","year":"2008","unstructured":"Andersen SL, Teicher MH (2008) Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci 31:183\u2013191. https:\/\/doi.org\/10.1016\/j.tins.2008.01.004","journal-title":"Trends Neurosci"},{"key":"2587_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1192\/bjp.179.3.218","volume":"179","author":"E Fombonne","year":"2001","unstructured":"Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M (2001) The Maudsley long-term follow-up of child and adolescent depression: 2. Suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 179:218\u2013223. https:\/\/doi.org\/10.1192\/bjp.179.3.218","journal-title":"Br J Psychiatry"},{"key":"2587_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1176\/appi.ajp.2007.06101757","volume":"164","author":"S Zisook","year":"2007","unstructured":"Zisook S, Lesser I, Steward JW, Wisniewski SR, Balasubramani GK, Fava M et al (2007) Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 164:1539\u20131546. https:\/\/doi.org\/10.1176\/appi.ajp.2007.06101757","journal-title":"Am J Psychiatry"},{"key":"2587_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/s2045796011000746","volume":"21","author":"G de Girolamo","year":"2012","unstructured":"de Girolamo G, Dagani J, Purcell R, Cocchi A, McGorry PD (2012) Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiol Psychiatr Sci 21:47\u201357. https:\/\/doi.org\/10.1017\/s2045796011000746","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"7","key":"2587_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jama.292.7.807","volume":"292","author":"J March","year":"2004","unstructured":"March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292(7):807\u2013820. https:\/\/doi.org\/10.1001\/jama.292.7.807","journal-title":"JAMA"},{"issue":"5","key":"2587_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/00004583-199905000-00018","volume":"38","author":"PJ Ambrosini","year":"1999","unstructured":"Ambrosini PJ, Wagner KD, Biederman J, Glick I, Tan C, Elia J et al (1999) Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 38(5):566\u2013572. https:\/\/doi.org\/10.1097\/00004583-199905000-00018","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"2587_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.290.8.1033","volume":"290","author":"KD Wagner","year":"2003","unstructured":"Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Sertraline Pediatric Depression\nStudy Group et al (2003) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290(8):1033\u20131041. https:\/\/doi.org\/10.1001\/jama.290.8.1033","journal-title":"JAMA"},{"issue":"7","key":"2587_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1089\/cap.2012.0023","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Robb A, Bose A (2013) Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. J Child Adolesc Psychopharmacol 23(7):468\u2013480. https:\/\/doi.org\/10.1089\/cap.2012.0023","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10047","key":"2587_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","volume":"388","author":"A Cipriani","year":"2016","unstructured":"Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C et al (2016) Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 388(10047):881\u2013890. https:\/\/doi.org\/10.1016\/S0140-6736(16)30385-3","journal-title":"Lancet"},{"key":"2587_CR19","first-page":"26","volume":"18","author":"JB Dwyer","year":"2019","unstructured":"Dwyer JB, Bloch MH (2019) Antidepressants for pediatric patients. Curr Psychiatr 18:26-42F","journal-title":"Curr Psychiatr"},{"key":"2587_CR20","unstructured":"National Institute for Health and Care Excellence (2019) Depression in children and young people: identification and management. NICE guideline [NG134]. https:\/\/www.nice.org.uk\/guidance\/ng134"},{"issue":"3","key":"2587_CR21","doi-asserted-by":"publisher","first-page":"e20174082","DOI":"10.1542\/peds.2017-4082","volume":"141","author":"AH Cheung","year":"2018","unstructured":"Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK, GLAD-PC STEERING GROUP (2018) Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. Pediatrics 141(3):e20174082. https:\/\/doi.org\/10.1542\/peds.2017-4082","journal-title":"Pediatrics"},{"issue":"5","key":"2587_CR22","doi-asserted-by":"publisher","first-page":"CD013674","DOI":"10.1002\/14651858.CD013674.pub2","volume":"5","author":"SE Hetrick","year":"2021","unstructured":"Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB et al (2021) New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev 5(5):CD013674. https:\/\/doi.org\/10.1002\/14651858.CD013674.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2587_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","volume":"7","author":"X Zhou","year":"2020","unstructured":"Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR et al (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 7(7):581\u2013601. https:\/\/doi.org\/10.1016\/S2215-0366(20)30137-1","journal-title":"Lancet Psychiatry"},{"issue":"10128","key":"2587_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y et al (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391(10128):1357\u20131366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7","journal-title":"Lancet"},{"key":"2587_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fpsyt.2020.00717","volume":"11","author":"K Boaden","year":"2020","unstructured":"Boaden K, Tomlinson A, Cortese S, Cipriani A (2020) Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment. Front Psychiatry 11:717. https:\/\/doi.org\/10.3389\/fpsyt.2020.00717","journal-title":"Front Psychiatry"},{"issue":"3","key":"2587_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/camh.12291","volume":"23","author":"IM Goodyer","year":"2018","unstructured":"Goodyer IM (2018) Editorial perspective: antidepressants and the depressed adolescent. Child Adolesc Ment Health 23(3):137\u2013140. https:\/\/doi.org\/10.1111\/camh.12291","journal-title":"Child Adolesc Ment Health"},{"issue":"3","key":"2587_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1600-0447.2006.00951.x","volume":"115","author":"C Moreno","year":"2007","unstructured":"Moreno C, Arango C, Parellada M, Shaffer D, Bird H (2007) Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand 115(3):184\u2013195. https:\/\/doi.org\/10.1111\/j.1600-0447.2006.00951.x","journal-title":"Acta Psychiatr Scand"},{"issue":"15","key":"2587_CR28","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Moca\u00ebr E (2014) Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 171(15):3604\u20133619. https:\/\/doi.org\/10.1111\/bph.12720","journal-title":"Br J Pharmacol"},{"key":"2587_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.g1888","volume":"348","author":"D Taylor","year":"2014","unstructured":"Taylor D, Sparshatt A, Varma S, Olofinjana O (2014) Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 348:1\u201319. https:\/\/doi.org\/10.1136\/bmj.g1888","journal-title":"BMJ"},{"key":"2587_CR30","doi-asserted-by":"publisher","first-page":"e87763","DOI":"10.1371\/journal.pone.0087763","volume":"9","author":"R Robillard","year":"2014","unstructured":"Robillard R, Naismith SL, Smith KL, Rogers NL, White D, Terpening Z et al (2014) Sleep-wake cycle in young and older persons with a lifetime history of mood disorders. PLoS ONE 9:e87763. https:\/\/doi.org\/10.1371\/journal.pone.0087763","journal-title":"PLoS ONE"},{"key":"2587_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1503\/jpn.130247","volume":"40","author":"R Robillard","year":"2015","unstructured":"Robillard R, Hermens DF, Naismith SL, White D, Rogers NL, Ip TK et al (2015) Ambulatory sleep-wake patterns and variability in young people with emerging mental disorders. J Psychiatry Neurosci 40:28\u201337. https:\/\/doi.org\/10.1503\/jpn.130247","journal-title":"J Psychiatry Neurosci"},{"key":"2587_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fpsyt.2018.00624","volume":"9","author":"R Robillard","year":"2018","unstructured":"Robillard R, Carpenter JS, Feilds KL, Hermens DF, White D, Naismith SL et al (2018) Parallel changes in mood and melatonin rhythm following an adjunctive multimodal chronobiological intervention with agomelatine in people with depression: a proof of concept open label study. Front Psychiatry 9:624. https:\/\/doi.org\/10.3389\/fpsyt.2018.00624","journal-title":"Front Psychiatry"},{"issue":"2","key":"2587_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S2215-0366(21)00390-4","volume":"9","author":"C Arango","year":"2022","unstructured":"Arango C, Buitelaar JK, Fegert JM, Olivier V, P\u00e9n\u00e9laud PF, Marx U et al (2022) Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet Psychiatry 9(2):113\u2013124. https:\/\/doi.org\/10.1016\/S2215-0366(21)00390-4","journal-title":"Lancet Psychiatry"},{"key":"2587_CR34","volume-title":"Manual: children\u2019s depression rating scale-revised","author":"E Poznanski","year":"1996","unstructured":"Poznanski E, Mokros H (1996) Manual: children\u2019s depression rating scale-revised. Western Psychological Services, Los Angeles"},{"key":"2587_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1744-859X-8-4","volume":"8","author":"Q Jiang","year":"2009","unstructured":"Jiang Q, Ahmed S (2009) An analysis of correlations among four outcome scales employed in clinical trials of patients with major depressive disorder. Ann Gen Psychiatry 8:4. https:\/\/doi.org\/10.1186\/1744-859X-8-4","journal-title":"Ann Gen Psychiatry"},{"issue":"12","key":"2587_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/01.chi.0000183464.41777.c1","volume":"44","author":"DB Clark","year":"2005","unstructured":"Clark DB, Birmaher B, Axelson D, Monk K, Kalas C, Ehmann M et al (2005) Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44(12):1263\u20131270. https:\/\/doi.org\/10.1097\/01.chi.0000183464.41777.c1","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"2587_CR37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1176\/appi.ajp.2009.08111620","volume":"166","author":"J March","year":"2009","unstructured":"Treatment for Adolescents with Depression Study (TADS) Team, March J, Silva S, Curry J, Wells K, Fairbank J, Burns B et al (2009) The Treatment for Adolescents with Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 166(10):1141\u20131149. https:\/\/doi.org\/10.1176\/appi.ajp.2009.08111620","journal-title":"Am J Psychiatry"},{"issue":"6","key":"2587_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/cap.2019.0176","volume":"30","author":"RL Findling","year":"2020","unstructured":"Findling RL, McCusker E, Strawn JR (2020) A randomized, double-blind, placebo-controlled trial of vilazodone in children and adolescents with major depressive disorder with twenty-six-week open-label follow-up. J Child Adolesc Psychopharmacol 30(6):355\u2013365. https:\/\/doi.org\/10.1089\/cap.2019.0176","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2587_CR39","doi-asserted-by":"publisher","first-page":"580858","DOI":"10.3389\/fphar.2020.580858","volume":"11","author":"W Kong","year":"2020","unstructured":"Kong W, Deng H, Wan J, Zhou Y, Zhou Y, Song B et al (2020) Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Pharmacol 11:580858. https:\/\/doi.org\/10.3389\/fphar.2020.580858","journal-title":"Front Pharmacol"},{"issue":"2","key":"2587_CR40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F et al (2020) Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry 19(2):214\u2013232. https:\/\/doi.org\/10.1002\/wps.20765","journal-title":"World Psychiatry"},{"issue":"6","key":"2587_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1089\/cap.2016.0024","volume":"26","author":"E Salardini","year":"2016","unstructured":"Salardini E, Zeinoddini A, Kohi A, Mohammadi MR, Mohammadinejad P, Khiabany M et al (2016) Agomelatine as a treatment for attention-deficit\/hyperactivity disorder in children and adolescents: a double-blind, randomized clinical trial. J Child Adolesc Psychopharmacol 26(6):513\u2013519. https:\/\/doi.org\/10.1089\/cap.2016.0024","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2587_CR42","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archpsyc.64.10.1132","volume":"64","author":"JS March","year":"2007","unstructured":"March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al (2007) The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:1132\u20131143. https:\/\/doi.org\/10.1001\/archpsyc.64.10.1132","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"2587_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.4088\/JCP.08m04548","volume":"70","author":"GM Goodwin","year":"2009","unstructured":"Goodwin GM, Emsley R, Rembry S, Rouillon F, Agomelatine Study Group (2009) Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70(8):1128\u20131137. https:\/\/doi.org\/10.4088\/JCP.08m04548","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"2587_CR44","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4088\/JCP.11m07493","volume":"73","author":"DJ Stein","year":"2012","unstructured":"Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C (2012) Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 73(7):1002\u20131008. https:\/\/doi.org\/10.4088\/JCP.11m07493","journal-title":"J Clin Psychiatry"}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-024-02587-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02587-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:09:14Z","timestamp":1748516954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-024-02587-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2587"],"URL":"https:\/\/doi.org\/10.1007\/s00787-024-02587-4","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. Dr. Fegert has no potential conflicts with pharmaceutical companies to report during the past 3\u00a0years. Dr. Buitelaar has been in the past 3\u00a0years a consultant to \/ member of advisory board of \/ and\/or speaker for Takeda, Roche, Medice, Angelini, Janssen, Boehringer-Ingelheim, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Fran\u00e7oise Picarel-Blanchot, Ute Marx, Lucie Truffaut-Chalet, and Pierre-Fran\u00e7ois Penelaud are Servier employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in strict accordance with Good Clinical Practice. The patients (when intellectual maturity and capacity were appropriate) and their parents or their legally authorised representatives provided written informed consent prior to participation, in line with local regulatory requirements. The study was registered under EUDRACT No. 2015-002181-23.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}